Mary McGrath

Dr. Mary McGrath

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMary McGrath
Mary McGrath
BWBrian Jackson Wentworth
Brian Jackson Wentworth
The renin–angiotensin system (RAS) is a complex homeostatic entity with multiorgan systemic and local effects. Traditionally, RAS works in conjunction with the kidney to control effective arterial circulation, systemic vascular resistance, and electrolyte balance. However, chronic hepatic injury and resulting splanchnic dilation may disrupt this delicate balance. The role of RAS in liver disease, however, is even more extensive, modulating hepatic fibrosis and portal hypertension. Recognition of an alternative RAS pathway in the past few decades has changed our understanding of RAS in liver disease, and the concept of opposing vs. “rebalanced” forces is an ongoing focus of research. Whether RAS inhibition is beneficial in patients with chronic liver disease appears to be context-dependent, but further study is needed to optimize clinical management and reduce organ-specific morbidity and mortality. This review presents the current understanding of RAS in liver disease, acknowledges areas of uncertainty, and describes potential areas of future investigation.

29 August 2024 in ACG Case Reports Journal
Verified
Journal Article
Open access
MMMary McGrath
Mary McGrath
CGCalvin Geng
Calvin Geng
ARAnthony Rainho
Anthony Rainho
EFEsteban Figueroa
Esteban Figueroa
Splenic abscesses are typically infectious in nature but have rarely been reported as an extraintestinal manifestation of inflammatory bowel disease, particularly of Crohn's disease. In the United States, reported cases are even more scarce. We present a case of aseptic splenic abscess with concomitant Sweet syndrome in a middle-aged woman with newly diagnosed Crohn's disease. Extensive workup was required to reach final diagnosis, and she rapidly improved with corticosteroid therapy and has been maintained on risankizumab. We aim to contribute to limited data and heighten clinician awareness of these atypical extraintestinal manifestations.

1 December 2025 in ACG Case Reports Journal
Verified
Journal Article
Open access
OBOlivia Becker
Olivia Becker
DSDeepika Suresh
Deepika Suresh
MMMary McGrath
Mary McGrath
HLHannah Laird
Hannah Laird
CACurtis Argo
Curtis Argo
NSNeeral Shah
Neeral Shah
Bronchobiliary fistula (BBF) is an atypical passageway between the biliary system and the bronchial tree. There are scarce reports of BBF and even fewer in living donor liver transplant (LDLT) recipients. We present a case of BBF in a 36-year-old woman who developed a bilious cough 2 years after a LDLT that was complicated by a late bile leak. We conclude that BBF should be considered in LDLT recipients who develop a bile leak postoperatively, given this common risk factor among reviewed cases. We support the use of hepatobiliary scintigraphy for diagnosis and noninvasive approaches aimed at decompression for repair.

12 February 2026 in JGH Open
Verified
Journal Article
Open access
BWBrian Jackson Wentworth
Brian Jackson Wentworth
MSMohammed Shwetar
Mohammed Shwetar
IMIndika Mallawaarachchi
Indika Mallawaarachchi
SRSarah Ratcliffe
Sarah Ratcliffe
MMMary McGrath
Mary McGrath
NSNeeral Shah
Neeral Shah
Background and Aims: Spontaneous bacterial peritonitis (SBP) is common in decompensated cirrhosis and often accompanied by large volume ascites. However, the safety of early therapeutic paracentesis is unknown and may lead to unnecessary delay in procedural performance. We aimed to assess whether paracentesis performance characteristics in the setting of SBP influenced renal or circulatory outcomes. Methods: A single‐center, retrospective cohort study was performed involving adult patients diagnosed with SBP based on ascites fluid studies during index admission between 2010 and 2020. Patient and procedural characteristics were collected and analyzed with respect to paracentesis timing (early vs. delayed) and volume (diagnostic only vs. non‐large volume therapeutic vs. large volume therapeutic). The primary outcome was a composite of the development of AKI and/or circulatory dysfunction. Secondary outcomes included 30‐day mortality, 90‐day mortality, and change in baseline renal function. Results: One‐hundred forty‐four patients met inclusion criteria during the study timeframe (Child‐Pugh C 74%, mean MELD‐Na 25). Sixty‐six (46%) met ACLF criteria at the time of SBP diagnosis. One‐hundred eight (75%) patients underwent a therapeutic paracentesis, of which approximately two‐thirds were performed within 24 h of admission (early); 41% were large volume (≥ 5 L of ascites removed). There was no difference in rates of the primary outcome with respect to either paracentesis timing or volume. Short‐term mortality and change in baseline renal function were independent of procedural characteristics. Conclusions: Therapeutic paracentesis does not appear to induce renal or circulatory dysfunction in patients with SBP.

24 February 2026 in JGH Open
Verified
Journal Article
Open access
PDF file
LLLaura E. Lavette
Laura E. Lavette
MMMary McGrath
Mary McGrath
SKSahil Khanna
Sahil Khanna
MSMatthew K. Schliep
Matthew K. Schliep
THTaylor M. Horgan
Taylor M. Horgan
BWBrian Jackson Wentworth
Brian Jackson Wentworth
Background and Aims: Optimal steroid induction therapy in autoimmune hepatitis (AIH) is unclear. We aimed to investigate the relationship between steroid dosing, route of administration, and time to biochemical response to help standardize AIH practice patterns and reduce excess steroid exposure. Methods: We conducted a retrospective cohort study of adult patients with non‐severe AIH receiving induction steroid therapy. Patients were stratified into three treatment groups: (1) low‐dose oral steroids ( n = 39; prednisone < 40 mg/day or budesonide 9 mg/day), (2) high‐dose oral steroids ( n = 32; prednisone 40 mg/day), and (3) intravenous steroids ( n = 21; methylprednisolone 1 g/day). Time to biochemical response and predictors of biochemical response were compared at 6‐ and 12‐month intervals. Results: Rates of biochemical response were similar between the low‐ and high‐dose oral steroid groups at 6 months (72% vs. 78%, p = 0.54) and 12 months (92% vs. 91%, p = 1.00). Regarding high‐dose oral versus IV steroid induction, rates of biochemical response were similar between groups at 6 months (78% vs. 86%, p = 0.72) and 12 months (91% vs. 90%, p = 1.00). Time to biochemical response was not significantly different across all groups at both 6 and 12 months (log‐rank test, p = 0.23 and p = 0.42, respectively). Initial biomarkers of disease severity were not predictive of time to biochemical response across groups. Conclusions: Lower dose prednisone may be an effective initial induction regimen in outpatients with AIH. Similarly, oral steroids may be non‐inferior to IV steroids. Together, these results favor a more conservative approach for non‐severe AIH induction therapy.